The Evolving Role of Pathology to Guide Precision Care Decisions in Myelodysplastic Syndromes

The Evolving Role of Pathology to Guide Precision Care Decisions in Myelodysplastic Syndromes

Saturday, October 8, 2022
Webinar -- 6:30 PM ET
https://www.clinicaloptions.com/NewOrleansMDS2022Join1

Agenda

  • Welcome and Introduction
  • MDS Classification Schemes and Pathology Workup
  • The Pathologists’ Assessment of Ring Sideroblasts and SF3B1 Mutations
  • “Tying It All Together” Case Discussion: Evidence-Based Treatment Strategies for MDS-RS and MDS/MPN-RS-T
  • Key Takeaways
  • Audience Question and Answer

Faculty

Faculty
Tal Oren, MD, PhD

Faculty
Alexa Siddon, MD

Faculty
Cecilia Yeung, MD

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to accurately diagnose and provide evidence-based treatment strategies for patients with MDS-RS and MDS/MPN-RS-T.

Target Audience
This educational program is intended for pathologists, hematopathologists, hematologists, hematologists/oncologists, and other healthcare professionals involved in precision care of MDS.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Formulate an actionable diagnostic workup plan for MDS with ring sideroblasts and MDS/MPN with ring sideroblasts and thrombocytosis considering ring sideroblast quantification and evaluation, current guidelines, and clinical evidence
  • Ascertain the clinical rationale for SF3B1 testing combined with ring sideroblast assessment in the diagnosis of MDS, based on the currently available data, guidelines, and expert recommendations
  • Identify technologies available to pathologists that can be used to test for SF3B1 mutations
  • Integrate into practice adequate sampling and sampling types for the accurate diagnosis of MDS with ring sideroblasts and MDS/MPN with ring sideroblasts and thrombocytosis to guide treatment decisions

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.